News

Julio J. Fernandez-Mendoza, PhD, a clinician-scientist at Penn State Hershey Sleep Research & Treatment Center, of Penn State Health, spoke to the implications of a recent study he and colleagues conducted.

Advanced imaging shows Parkinson disease can begin as brain-first or body-first.

Here's what is coming soon to NeurologyLive.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center provided insight on the lapses in levodopa-carbidopa treatment and what potential changes could come in the future.

The results confirmed that roughly almost 15% of cases are linked to genes and ultimately led to recommendations for more tailored treatments of 3 patients.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

Jonathan Graff-Radford, MD, neurologist at Mayo Clinic, discussed how recent diagnostic advancements have propelled research efforts into uncharted territory.

The use of statins was also associated with a reduced risk of SUDEP, but there were no reduced risks with SSRIs or other antidepressants, neuroleptics, or beta-blockers.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center shared the reasons why LCIG is underused in clinical care.

Zosano Pharma noted that the DRL does not reflect the final FDA decision on the application, though the approval of zolmitriptan by its PDUFA action date of October 20, 2020, is no longer likely as a result.

The primary objective of the trial is to demonstrate that lorcaserin has superior efficacy compared to placebo as measured by percent change in frequency of convulsive seizures per 28 days.

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

The findings were consistent with the drug's previously reported safety profile and no new safety signals were observed.

The investigators noted that continuous non-invasive blood pressure monitoring upon standing may aid in the identification of a modifiable risk factor for syncope-related falls in patients with Parkinson disease.

Volumetric MRI shows Hispanic patients are at a greater risk of experiencing more aggressive disease, leading to sustained disability.

The neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.

The funding will offer additional benefit for the HABLE and HABLE-AT(N) studies with the ability to better classify and categorize participants into groups by dementia type and disease stage.

Post hoc analysis of the ATACH-II trial suggest that intensive lowering of systolic blood pressure in individuals with initial levels ≥220 mmHg increases the rate of neurological deterioration over 24 hours.

Learn more about the 2020 Dash For Dravet, hosted by the Dravet Syndrome Foundation.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine discussed the role amyloid plays in various types of Alzheimer disease and its impact on vascular dysfunction.

The vaccine could be given therapeutically to individuals living with a diagnosis of AD to inhibit further disease progression.

The director of the Parkinson’s Foundation Center for Excellence at University of Kansas Medical Center detailed the pros and cons of levodopa-carbidopa intestinal gel.

The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.

Aquestive Therapeutics plans to provide the agency with information on pharmacokinetic modeling to demonstrate that the desired levels of diazepam exposure can be achieved with dose adjustments.

The platform, dubbed DystoniaNet, was able to identify 3 varieties of focal dystonia in a matter of 0.36 seconds with almost 100% accuracy.

The study investigators noted that a higher gravidity and parity number was not associated with a delay in CIS onset.

Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.